C. Ola Landgren Hematology Society of Taiwan

Carl Ola Landgren: Can MRD serve as early endpoint for accelerated approval in myeloma, to facilitate patient’s access to new drugs

Carl Ola Landgren, Professor of Medicine, Chief of Myeloma Division at University of Miami, shared a post on X:

“I started the EVIDENCE meta-analysis in 2009. After 15 years of work, I will present 4/12 at ODAC: Can MRD serve as early endpoint for accelerated approval in myeloma, to facilitate patient’s access to new drugs?”

Procced to the video.
Source: Carl Ola Landgren/X

cancer Carl Ola Landgren EVIDENCE meta-analysis multiple myeloma Myeloma Myeloma MRD ODAC OncoDaily Oncology oncology drug advisory committe University of Miami